Funded Projects

This team aims to revolutionize future stroke treatment both in clinics and at home by combining a brain-computer interface and augmented reality (AR) into a single rehabilitation platform.

This team aims to advance augmentative and alternative communication technology for people with communication disorders and enable new forms of human-computer interaction by combining novel materials science with modern machine learning.

We propose a new line of research whose goal is to examine the druggability of a protein-protein interface involving ApoE, an apolipoprotein whose gene variants represent the strongest genetic risk factor for AD.

People with Parkinson’s Disease (PD) have different types of bacteria in their guts compared to people without neurological diseases. We will study which gut bacteria for people with PD to gain a better understanding of how gut bacteria contribute to inflammation in the body and in the brain or people with this condition. 

We propose to apply mass spectrometry techniques to measure BHB-Phe and other KD metabolites in children undergoing KD for refractory epilepsy at Stanford. Further, in a mouse model of refractory genetic epilepsy, we will compare targeted BHB-Phe treatment to full KD treatment using transcriptomics, EEG assessment of seizures and cognitive testing.

Why do all our brains mature and age in different ways, leading to different cognitive and behavioral outcomes? We envision a novel method that “copies” the information from the RNAs made by the neurons to sensor RNAs we artificially introduce into live animals. 

In this study, we aim to (i) perform a feasibility study to determine the acceptance and feasibility of performing such recordings in the AN and ARFID eating disorders population and (ii) test the hypothesis that the electrophysiologic monitoring of the brain and stomach is associated with a clinically validated behavioral measure of interoception involving water distention of the stomach.

This proposal brings together faculty with this diverse expertise to develop the first gold standard test of auditory-vocal affect. Once developed, validated, and normed, we will deploy this test in the clinical context of autism to quantify impairments and direct neurobiological investigation.

We will comprehensively define the gene network associated with mitochondrial dysfunction in Parkinson's disease using a cutting-edge technology, CRISPR, to understand how these nerve cells die in PD and how we can reverse the cell death to treat the disease.

Maternal infection is linked to increased risk of neurodevelopmental disorders such as autism and schizophrenia. This proposal examines how virus-associated cytokines, specifically interferons, affect human neurons modeled in brain organoids or studied directly in fetal brain samples.